HPGDS inhibitor 1 is primarily utilized in research focused on inflammation and allergic responses. It targets hematopoietic prostaglandin D synthase (HPGDS), an enzyme involved in the production of prostaglandin D2, which plays a key role in inflammatory and allergic conditions such as asthma, atopic dermatitis, and allergic rhinitis. By inhibiting HPGDS, this compound helps reduce the levels of prostaglandin D2, thereby mitigating inflammation and allergic symptoms. It is particularly valuable in preclinical studies to understand the pathways and mechanisms of these conditions, as well as in the development of potential therapeutic agents for inflammatory and allergic diseases.